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The interactions between the nervous and immune systems have been recognized in the
development of neurodegenerative disease. This can be exploited through detection of the immune
response to autoantigens in assessing the neurotoxicity of environmental chemicals. To test this
hypothesis, the following questions were addressed. a) Are autoantibodies to nervous system (NS)
antigens detected in populations exposed to environmental or occupational chemicals? In sera of
male workers exposed to lead or mercury, autoantibodies, primarily IgG, to neuronal cytoskeletal
proteins, neurofilaments (NFs), and myelin basic protein (MBP) were prevalent. These findings
were confirmed in mice and rats exposed to either metal. b) Do autoantibodies to NS antigens
relate to indices of exposure? In humans exposed to either metal, and similarly in exposed rats,
titers of lgG against NFs and MBP significantly correlated with blood lead or urinary mercury, the
typical indices of exposure. c) Do autoantibodies correlate with sensorimotor deficits? In workers
exposed to lead or mercury, a significant correlation was observed between lgG titers and
subclinical deficits. Doses of metals used in rat exposures were subclinical, suggesting that
autoantibodies may be predictive of neurotoxicity. d) Is the detection indicative of nervous system
pathology? In rats exposed to metals, histopathology indicated central nervous system (CNS) and
peripheral nervous system (PNS) damage. In addition there was evidence of astrogliosis, which is
indicative of neuronal damage in the CNS, and the presence of lgG concentrated along the
blood-brain barrier, as indicated by immunostaining for antibodies. e) Are immune responses to NS
antigens pathogenic? Immunoglobulin fractions from rat and human sera interfered with
neuromuscular function. These studies suggest that the detection of autoantibodies to NS-specific
antigens may be used to monitor the development of neurotoxicity to environmental chemicals and
that immune mechanisms may be involved in the progression of neurodegeneration. Key words:
autoantibodies, autoimmunity, biomarkers, heavy metals, neurodegeneration, neuropathology, risk
assessment. - Environ Health Perspect 107(suppl 5):767-775 (1999).
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The inaccessibility ofthe nervous system has
long posed a challenge to neuroscientists and
in particular to neurotoxicologists. This inac-
cessibilityhas impeded the evaluation ofcellu-
lar and molecular changes associated with the
initial changes ofneurotoxicity, prior to overt
clinical deficits in live animals and humans.
Current methods ofassessing the develop-
ment ofand recovery from neurotoxic insult
include behavioral, electrophysiologic, and
brain imaging techniques (1,2). However,
these evaluations require highly trained per-
sonnel, are costly, and do not identify specific
cellular substrates or mechanisms. This
imposes limitations to their utility in clinical
diagnostics, risk assessment, and their applica-
bility to populations in the exposure arena
(e.g., agriculture, industry). Furthermore, the
detection ofdeficits often does not occur in
the absence ofovert manifestations.
O'Callaghan (3,4) has proposed that
neurotypic and gliotypic proteins be used to
detect and characterize the cellular response to
toxicant-induced injury. Alterations in nervous
system-specific proteins; for example, glial fib-
rillary acidic protein (GFAP), the astrocytic
intermediate filament, maybe expressed at low
exposure levels of neurotoxic metals and
toluene (3,5-7) and other nervous system
insults. This reactive gliosis occurs secondary
to neuronal insult and degeneration. Although
direct measurement ofproteins in the brain
may provide valuable insights into the cellular
targets of neurotoxicity in animal studies
(3,8,9), they are not applicable to human pop-
ulations. However, this evidence should prove
invaluable in evaluating potential biomarkers
ofneurotoxicity.
We have proposed that exposure to
neurotoxic agents and the attendant neuro-
degeneration with the liberation of neural
proteins can induce an autoimmune response
conveniently measurable in blood. This
immune response is reflected in the produc-
tion ofserum autoantibodies against nervous
system proteins and activation oflympho-
cytes. Surprisingly, few neurotoxicology
studies have investigated the possible involve-
ment ofthe immune system and autoimmu-
nity as a marker or as an effector in the
development ofneurotoxicity.
Neurocytology, Immunology,
and Immunoprivilege
It is well established that the nervous system
comprises the heterogeneous cell populations.
Neurons, the excitable elements of the
nervous system, are considered synonymous
with nervous system function. These are the
cells responsible for detecting intrinsic and
extrinsic environmental stimuli (sensory
function), communicating these stimuli for
interpretation (brain and spinal cord func-
tion), and formulating appropriate responses
to these stimuli (motor function). Despite
their being the minority cells ofthe nervous
system, neurons control and regulate body
function, thus placing them in a unique posi-
tion ofvulnerability. Neuroglia, astrocytes,
oligodendrocytes, Schwann cells, and
microglia are the majority cells. Functionally
they provide protection, influencing electrical
conductive properties of the neuronal axons
and dendrites. Astrocytes, Schwann cells, and
central macrophages (microglia), however,
may play a role in immune activation within
the nervous system.
Astrocytes may play a role in the
regulation of inflammation and immune
responses in the central nervous system (10).
Astrocytes release interleukin (IL)-1 in
response to substance P stimulation (11) and
produce tumor necrosis factor (TNF)-oc in
response to viral infection (12,13) and bacte-
rial lipopolysaccharide (LPS) (14). Viral or
LPS stimulation induce the gene expression
ofIL-la; IL-11; IL-6, and interferon (IFN)-
y by astrocytes (12). Astrocytes also secrete
IL-3, which induces microglial proliferation
(15,16), suggesting a cooperative role
between astrocytes and microglia during cell
injury. Astrocytes also produce complement
factors C3 and B (17). Astrocytes not only
produce cytokines and complement factors
but also respond to cytokine stimulation.
Human astrocytes proliferate in response to
TNF-a. This is accompanied by downregu-
lation ofGFAP expression (18). Stimulation
of murine and human astrocytes by
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IFN-y enhances their expression ofclass II
major histocompatibility complex (MHC)
(19,20). Astrogliosis, the astrocytic prolifera-
tive response to neuronal injury, may be in
response to IFN-y (21), whereas it is down-
regulated by IL-4 (22).
Although astrocytes may not act as the
major antigen-presenting cells (APCs),
microglia act as APCs in the brain. These are
among the first cells to be recruited in
response to injury (23). In turn, microglia
may stimulate astrocytes following injury
through the production ofTNF-a, IL-1 ,
and IL-6 (23,24-26). The proliferation and
APC activity ofmicroglia has been shown to
be stimulated by IFN-y, colony-stimulating
factor ofmacrophages (16,27,28). Microglia
express both MHC I and MHC II, indicat-
ing their immunocompetence (29).
Expression of both MHC I and II suggests
that microglia may stimulate both T-helper
(Th) and cytotoxic T cells (30).
Similarly, in the peripheral nervous
system (PNS), Schwann cells respond in vivo
and in vitro to IFN-,y and TNF and express
MHC I and II (31,32). This ability ofmyeli-
nating Schwann cells to act as APCs has been
documented following peripheral nerve crush
and in peripheral nerve disease (33,34).
Under normal circumstances, the nervous
systems, both central and peripheral, are con-
sidered relatively immunoprivileged, as pro-
vided by the blood-brain barrier (BBB) and
blood-nerve barrier (BNB). The BBB con-
sists ofspecialized endothelial cells with tight
junctions, pericytes, and bone marrow-
derived perivascular elements. These are
enclosed within a basal lamina and astrocyte
foot processes (35). On the other hand, the
BNB is formed by the permeable epineurium,
the tight junctions ofthe perineurium, and
the impermeable endoneurium (35 ). These
barriers control the selective entry ofessential
biomolecules, induding glucose, and exclude
potentially harmful elements, including
immune cells. However, this immuno-
privileged status may be lost as a result of
nervous system injury.
Interactions between Nervous
and Immune Systems
As mentioned above, evidence has accumulated
that glial cells (astrocytes, microglia, and
Schwann in the periphery) play more than
structural roles in the nervous system
(36,37). Can these cells, or their constituents
activate immune cells? GFAP (38) and
myelin basic protein (MBP) (39) are mito-
genic to cultured lymphocytes, in vitro. MBP
is also mitogenic to cultured gliaand lympho-
cytes. This evidence suggests that nervous sys-
tem proteins may activate lymphocyte
following demyelination or glial cell damage.
It has now become accepted that interactions
and similarities exist between the nervous and
immunesystems (10,40).
Consistent with the possible role ofglial
cells as APCs are reports oflymphocyte
infiltration across the BBB following its dis-
ruption (41,42) or if frank damage is
absent, by adhesion to endothelial cells of
the BBB (43-45). This adhesion and infil-
tration is modulated by intercellular adhe-
sion molecule-1 and by cytokines. The
presence ofT and B lymphocytes in nervous
system tissues and cerebral spinal fluid
(CSF) has been documented in humans
(e.g., multiple sclerosis [MS]) and in experi-
mental models of nervous system disease
(46,47). Experimental evidence indicates
that activated T-lymphocytes are capable of
entry into the central nervous system (CNS)
without a need for antigen-specific activa-
tion (48), and that the CNS is constantly
patrolled by a low but consistent number of
activated T-lymphocytes and monocytes.
This potential interaction between cells of
the nervous and immune systems may have
implications for the neurotoxicity of
environmental and occupational toxicants.
Autoimmune Responses
and Neurodegeneration
Autoimmune mechanisms have been recog-
nized in neurologic diseases such as myasthe-
nia gravis (49), Guillain-Barre syndrome (50),
and experimental allergic encephalomyelitis
(51). The nervous system itself may have
immunologic functions as noted earlier
(36,52). How nervous system antigens
encounter and interact with cells ofthe sys-
temic and lymphatic circulations and whether
this occurs in situ in the nervous system or the
periphery is not fully understood. This may
occur in the brain parenchyma, in the cervical
lymph nodes, excretion through the CSF, or at
the BBB (53). The presence ofnervous system
antigens, GFAP and MBP in particular, has
been documented in CSF ofadults and chil-
dren suffering from neurologic diseases, e.g.,
Alzheimer's disease and encephalitis (54-60).
However, assay ofthese proteins in peripheral
blood as markers ofneurotoxic insult may be
oflimited use in the presence ofextracellular
proteases. On the other hand, autoantibodies
against neurofilament triplet proteins (NFs) as
well as MBP and GFAP have been detected in
sera and CSF ofhuman subjectssuffering from
neurologic disorders, including Alzheimer's
disease, Parkinson dementia, amyotrophic lat-
eral sclerosis (ALS), Creutzfeldt-Jakob disease,
and kuru (61-67). Furthermore, autoanti-
bodies to neurotypic proteins have been
demonstrated in animal models ofallergic
encephalomyelitis and electroconvulsive shock
(68,69). The interaction ofenvironmental
chemicals, neurodegeneration, and auto-
immune responses hasyet to bedelineated.
NeurotoxicExposures and
Neuroimmune Interactions
As early as 1850, Aran (70) described a
progressive muscular atrophy, today known
as ALS or motor neuron disease. This was
associated with occupational exposure to
inorganic lead in some ofhis patients. Since
then, several studies have reported similar
observations with elevated levels of lead in
plasma, erythrocytes, CSF, and spinal cords
ofALS patients (71-74). Similarly, elevated
mercury has been reported in patients with
ALS (72,75,76). Heavy metals exposure has
also been suspected ofplaying a role in the
etiology of MS (77-80). In both ALS and
MS, autoantibodies against nervous system
proteins are detected. Forexample, autoanti-
bodies against NFs, MBP, GFAP, and GMI
ganglioside have been detected in sera and
CSF ofhuman subjects suffering from these
diseases (81-83). Anti-MBP antibodies are
cytotoxic and are believed to play a key role
in the pathogenesis of MS (65.81). More
recently the presence of autoantibodies to
the dihydropyridine calcium channel (the
Lchannel) has been demonstrated in sera of
ALS and Lambert-Eaton syndrome patients
(82). These autoantibody titers correlated
with disease progression. Such autoanti-
bodies are pathogenic, interfering with nerve
conduction, synaptogenesis, and neurite
growth (83-85).
A role for environmental toxicants,
particularly metals, in the development of
nervous system pathologies and the possible
involvement ofthe immune system are con-
sistent with the experimental observations
that metals, particularly lead, augment
immune responses. For example, lead
enhances B-lymphocyte differentiation
in vitro. In vivo it enhances the activity of
B lymphocytes toward T-cell-dependent
antigens (86-89) and enhances the produc-
tion ofantibody in vitro, as well as directly
activating B cells (90). Lead also enhances
the production and release of IL-2 from
Tlymphocytes (91), thus enhancing B-cell
responsiveness (90). These observations have
led to the suggestion that lead exposure may
result in an autoimmune response (90).
Highly relevant to the presence ofautoanti-
bodies are studies indicating that low levels
oflead enhance immunoglobulin synthesis
(86,92). In the presence ofchemical-induced
nervous system degeneration and continued
exposure to these chemicals, we believe that
lymphocytes can be stimulated to increase
autoantibody production. Several studies
have demonstrated an increase in serum
immunoglobulins following exposure to
mercury and lead (93). This increase in
serum immunoglobulins may reflect the
appearance ofautoantibodies.
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Neuropathies and
Cellular Antigens
Spencer and Schaumburg (94) and Chang
(95) have suggested a unifying classification
scheme for toxicant-induced neuropathy
based on the primary site of insult and the
subsequent secondary targets involved.
These categories include the following:
a) Neuronopathy, where the soma (cell body)
is the primary target, followed by secondary
nerve fiber degeneration (dying-forward),
tertiary myelin loss, and target cell atrophy
or death (trans-synaptic degeneration).
Neuronopathies are irreversible since neurons
are terminally differentiated. Agents such as
mercury, aluminum, and glutamate-induced
excitotoxicity are believed to precipitate this
type of insult. b) Axonopathies, where the
axons (or peripheral sensory fibers) primarily
targeted are believed to be the most common
nervous system injury, particularly the
exposed vulnerable peripheral nerves.
Axonopathies may progress proximo-distally
from the soma or die-back, progressing to a
neuronopathy. Secondarily, axonopathies are
associated with secondary myelin degenera-
tion in severe cases. Where the soma remains
functionally intact, chromatolysis and fiber
regeneration may occur. Toxicants inducing
axonopathies include acrylamide, hexacarbons,
and tri-o-cresyl phosphate. c) Myelinopathies,
or myelin gliopathy, involve either the myelin
sheath, such as in the case oftriethyltin, or the
myelinating cells, such as in the case ofethid-
ium bromide neurotoxicity. This may or may
not be followed by axonal degeneration. Less
well dassified is the damage that may occur to
astrocytes. It is suggested that astrocytes may
be primarily or secondarily targeted by some
neurotoxic agents.
In the nervous system, astrocytes act as
sites ofdeposition for heavy metals, including
mercury (96,97) and lead (98,99), where
these metals may modulate metabolic func-
tion (100,101). In this regard, astrocytes may
themselves be targets oflead and mercury,
resulting in their degeneration and death,
whether as a primary target or secondary to
astrogliosis (102-106). Similarly, other
chemicals may induce damage to glia.
Pilocarpine-induced epilepsy in rats resulted
in glial damage within the substantia nigra
and basal cortex (107). Recently, toluene
inhalation has been reported to result in a
reduction in the astrocyte-specific protein
GFAP (7). Additionally, some chemicals may
induce a vasculopathy, resulting in leakage of
barriers. Inorganic lead and cadmium fall
within this category (94).
On the basis of this classification, we
propose that detection ofimmune responses
to autoantigens characteristic of different
target sites may be used in identifying the
effects and specific targets ofthe neurotoxic
chemicals. Coupled with neuropathologic
assessment, these autoimmune responses can
be validated for experimental animal studies
and the monitoring ofhuman populations. A
summary ofpotential cellular targets and cellu-
lar antigens in the nervous system is presented
in Figure 1. Additional nervous system-specific
proteins are discussed by O'Callaghan (4) and
Linington and Brostoff(107).
Autoantibodies as Markers
of Nervous System Injury:
Rationale and Hypothesis
In our use ofthe term marker or biomarker, a
distinction is made here between markers of
exposure and markers ofeffect. For example,
blood lead levels are used to indicate exposure
to lead; they do not provide information on
the neurotoxicity oflead. It is inferred from
historical human and animal studies that a
particular blood level is associated with cer-
tain symptoms or lesion. Furthermore, this
inference is often based on detection ofovert
toxicity but does not delineate changes that
may be early predictors oftoxicity. A second
distinction is also made here. In the study of
the link between environmental chemicals,
autoimmunity, and the nervous system, we
distinguish between the concept ofimmuno-
logic biomarkers ofneurotoxicity, immune
mechanisms of neurotoxicity, and the
immunotoxic effects ofenvironmental chemi-
cals. The latter is discussed in other reviews.
The concept ofusing immunologic indicators
to reflect environmental exposure-induced
damage to other systems derives from the
definition of the immune system as a
Figure 1. Potential targets and autoantigens to which autoantibodies may be detected as a result of neurotoxicity.
Abbreviations: ChAT, choline acetyltransferase; CNS, central nervous system; MAPs, microtubule-associated pro-
teins; MT, microtube; NFs, neurofilament triplet proteins; PNS, peripheral nervous system. (1) Structural proteins of
the neuron such as the NFs, a- and P-tubulin of the MT, and MAPs. (2) Proteins of neurotransmission such as
sodium, potassium, and calcium channels or those associated with the vesicle-docking fusion essential for neuro-
transmitters release (e.g., synaptophysin, synapsin, synaptotagmin, latrototoxin receptor), or intracellular neurotrans-
mitter synthesizing enzymes (e.g., ChAT). (3) Proteins of the postsynaptic targets: neurons/muscle (e.g.,
neurotransmitter receptors, actin, myosin, desmin) or catabolic enzymes (e.g., acetylcholinesterase). (4) Proteins of
myelin and myelinating cells such as myelin basic protein and myelin-associated glycoprotein, common to both the
CNS and the PNS, or proteolipid protein, found only in CNS myelin. PO and peripheral myelin protein-22 of peripheral
myelin. (5) Proteins associated with astroglia of the CNS or the blood-brain barrier, such as glial fibrillary acidic pro-
tein, S-100, and vimentin (in developmental studies). Furthermore, although some neuronal proteins are widely dis-
tributed throughout the nervous system, others are restricted to only certain neurons or brain regions (G-substrate in
the cerebellum, DARPP-32 in the neostriatum, and SNAP-25 in the hippocampus). Proteins of the CNS and PNS are
reviewed in(4) and (107).
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functional system responsible for surveillance
of the host's various organ systems. The
immune system provides a unique opportu-
nity for the neurotoxicologist, particularly in
the reduction in the number ofexperimental
animals and in clinical toxicology, for assess-
ing the pathologic status of other systems.
This is facilitated by the relatively noninvasive
sampling and collection of sera and immune
cells. Although this approach has been used
successfully by toxicologists in the study of
other systems [reviewed in (108-112)], a
review of the literature reveals a paucity of
studies dealing with neurotoxic exposures and
autoimmune responses (113).
The generation of autoantibodies to
nervous system-specific antigens is feasible in
the presence ofneuronal death, axonal degen-
eration, demyelination, and glial death such
as that precipitated by neurotoxic agents in
the CNS or PNS. This exposes and liberates
intracellular antigens, often sequestered anti-
gens that the immune system has not encoun-
tered previously. Our hypothesis is
summarized in Figure 2. Proteins specific to
nervous system structures would be presented
as autoantigens by resident microglia in the
CNS or as infiltrating macrophages in the
PNS. This would result in a cellular and/or
humoral response with autoantibodies raised
against these autoantigens in the latter case.
The generation ofthese autoantibodies would
likely occur, particularly with metal intoxica-
tion, in light of their ability to compromise
blood barriers (103,104,114,115). In this
way, the immune system provides a means
whereby cellular damage in the nervous sys-
tem can be documented and measured in
serum, thereby eliminating the problems
associated with the inaccessibility of the
nervous system.
Autoantibodies in Humans
and Animals Exposed
to Neurotoxic Agents
The use ofautoantibody detection to indicate
nervous system insult was tested in our labora-
tory in several populations and verified in ani-
mal studies (Table 1). To illustrate the utility
of these assays, we will concentrate on results
obtained from inorganic lead exposures.
Autoantibodies and Exposure
Field testing of autoantibody assays was
performed by our laboratory in male workers
occupationally exposed to lead at a battery
factory (blood lead: 10-40 pg/dL) or mercury
vapor (urinary mercury: 6-30 ,ug/g creatine)
at a fluorescent light factory. In addition, a
reference group from a frozen food packing
plant with no prior work history of exposure
to either metal was also recruited (116-118).
All participants in the study were matched on
the basis ofdemographics and socioeconomic
status as well as on years of metal exposure.
Ambient mercury (as vapor) and lead (as dust
or fumes), 0.05 and 0.09 mg/m3, respec-
tively, are below or at the threshold limit
value-time weighted average (TLV-TWA)
adopted by the American Conference of
Governmental Industrial Hygienists.
Titers of autoantibodies (IgM and IgG
isotypes) to NF proteins NF-68, NF-160, and
NF-200; GFAP and MBPs were determined
/-
C BBB
RP -PCIL-6 y
A0 11' \_
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Figure 2. Hypothesis forthe induction and pathogenisis of autoantibodies to nervous system proteins during exposure to
environmental chemicals. Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; APC, antigen-presenting
cells; B, B lymphocyte; BBB, blood-brain barrier; BNB, blood-nerve barrier; CNS, central nervous system; IL, interleukin;
NP, nervous system protein; PNS, peripheral nervous system; T, T lymphocyte; Y, antibody. Following the initial insult(1)
by neurotoxic chemical to cells of the nervous system, autoantigens ([NP) see Figure 1) are released and (2) undergo
antigen processing and presentation by microglia, or astrocytes or macrophages. (3) This results inT-lymphocyte activa-
tion and stimulation of B lymphocytes by interleukin signaling (e.g., IL-6 and IL-2) to produce autoantibodies to these
autoantigens. This may occur in situwithin the nervous system or as a result of being extruded into the peripheral circu-
lation. The perception thatthese antigens areforeign isfacilitated bythe presence of BBB and BNB. Inaddition, environ-
mental chemicals may act directly on the immune system to augmentthe development ofcellular or humoral responses.
(4) Autoantibodies (Y) may be pathogenic, contributing to the progression of the neuropathology or physiologic impair-
ment. Autoantibodies maydirectly induce damage to neurons orcompromisefunction bycomplexing to surface antigens,
fix-complement to precipitate neuronal death, ordamage neural tissue byADCC.
Table 1. Chemical exposures where autoantibodies to nervous system proteins are detected.
Exposure Medium Species Reference
Phenyl saligenin phosphate (po) Serum Chicken (155,156)
Lead acetate in drinking water Serum CBA/J mice (123)
Lead acetate in drinking water Serum ALAD mice (165,166)
Lead acetate in drinking water Serum Fischer 344 (120,133)
Trimethyl lead Serum Fischer 344 (168)
Methyl mercury in drinking water Serum Fischer 344 (121)
Cadmium chloride (po) Serum Fischer344 (171)
Trimethyl tin (ip) Serum Long Evans (171)
Cobalt Serum Sprague-Dawley (170)
Trimethyl lead in food CSF Macaque (171)
Toluene by inhalation Serum Macaque (171)
Cadmium in battery plant Plasma Human (172)
Lead in battery plant Serum Human (113,116,117)
Mercury in fluorescent light plant Serum Human (113,118)
Mercury (amalgam) Serum Human (170)
Trichloroethylene and solvents Serum Human (108)
Methamidophos Serum Human (173)
Pesticide mixtures Serum Human (174)
Abbreviations: CSF, cerebral spinal fluid; ip, intraperitoneal; po, per os.
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in sera ofexposed and reference populations
by an enzyme-linked immunosorbent assay
developed by El-Fawal et al. (119) against
these proteins. Summaries of individual
titers, the mean, and the percent of each
population with detectable immunoglobu-
lins (M and G isotypes) against NF-68 in all
three populations are presented in Figure 3.
Autoantibodies against neuroproteins predom-
inated in metal-exposed populations compared
to the reference population. The detection of
autoantibodies in a small percentage ofthe ref-
erence population probably reflects natural
autoantibodies, usually IgM, which are found
in some individuals (63,120).
The generation ofautoantibodies to these
antigens during lead or mercury exposure was
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Figure 3. Individual autoantibodies (IgM and IgG) titers
to NF68 in reference population and populations
exposed to lead at a battery plant or mercury in a fluo-
rescent light factory. NF, neurofilament. The y-axis is a
logl0 scale. Percentage positive values for anti-NF-68
are indicated below the x-axis. Horizontal lines and
boxes indicate means ± SEM. Autoantibody detection
predominated in exposed populations compared to the
reference group. The prevailing isotype in exposed
populations was lgG (see text).
1,000 -
100 -
10 -
1 -
o OgM 50 ppm Pb
* IgG 50 ppm Pb
O IgM 450 ppm Pb
R IgG 450 ppm Pb
0 10 20 30 40 50
Davs of Pb exwosure
Figure 4. Autoantibody (IgM and IgG) titers to NF-68 in
rats exposed to lead acetate at 50 and 450 ppm in the
drinking water. Abbreviations: Pb, lead; NF, neurofila-
ment. Control rats did not have detectable titers of
autoantibodies to the assayed antigens. The yaxis is a
logl0 scale. Each point represents the mean ± SEM for 7
rats. Autoantibodies were detected as early as 4 days of
exposure and were of the IgM isotype (primary
response). IgG was detected later, as isotype switching
occurs with no significant increases in IgM.
Furthermore, titers were significantly higher in animals
exposed to the higher dose (see text and Table 2).
confirmed (119,121). In studies with lead
(121), male Fischer 344 rats (> 42 days of
age) were exposed to 50 or 450 ppm lead
acetate in the drinking water. No overt signs
oftoxicity or changes in home-cage behavior
(122) were evident in any ofthe rats. Blood
lead levels ranged from 11 to 50 1ig/dL and
were comparable to those measured in
humans. While control rats had no detectable
titers to these particular antigens, titers of
autoantibodies, particularly IgM, were
detected and quantified as early as 4 days after
the initiation of lead exposure. IgG was
detected later. The detection ofanti-NF-68
and the time course are summarized in
Figure 4. The early detection of IgM is con-
sistent with a primary antigen challenge (in
this case autoantigens). There was significant
elevation ofIgM titers, followed by a gradual
isotype switching to IgG at later durations. In
both human and rat studies, autoantibody
levels, particularly anti-NFs, correlated signif-
icantly with blood lead-the index ofexpo-
sure for both humans and rats (Table 2).
To confirm the presence ofautoreactive
B lymphocytes expressing autoantibodies to
nervous system proteins, splenocyte prepara-
tions from lead-exposed rats and mice (123)
were challenged with LPS. Both IgM and IgG
against NFs, GFAP, and MBP were detected
in the splenic supernatants. Figure 5 shows
the 1gM response of LPS-stimulated rat
splenic cells at 7 days ofexposure. In mice the
production of autoantibodies from spleno-
cytes was accompanied by IL-6 and IL-2 pro-
duction by T lymphocytes (concanavalin
A-stimulated cultures). IL-6 is believed to
stimulate B-lymphocyte differentiation to
antibody-producing plasma cells and copro-
motes IL-2 production by mature T lympho-
cytes. IL-2 promotes secretion ofantibodies
from activated B lymphocytes and is consis-
tentwithTh-assisted B-cell responses (102).
Autoantibodies andClinical Deficits
In exposed human populations, antibody titers
that significantly correlated with exposure and
sensorimotor function were predominantly
IgG. IgG is the isotype mostcommonly associ-
ated with secondary antigen challenge or anti-
gen persistence and pathology (124). A
significant dose-response relationship between
the total number ofdetectable autoantibodies
ofthe G isotype (IgG score) to the five antigen
proteins and the total number ofupper and
lowerlimb sensorimotor deficits (clinical score)
was observed (Figure 6). This suggests an asso-
ciation between the appearance ofantibodies
in the sera and the neurotoxicity of metal
exposure. However, it must be emphasized
that sensorimotor deficits were subclinical and
notovert.
AntibodiesandCellularTargets
The neuropathology associated with chronic
exposures to mercury or lead primarily
involves the neuroaxon with secondary
demyelination (105,115,125). In the human
studies, anti-NFs, IgG isotype, were the most
frequently detected antibodies. These were
also the antibodies and the isotype best corre-
lated with blood lead or urinary mercury and
clinical scores ofsensorimotor deficits. This is
consistent with the type of neuropathy in
humans that manifests primarily neuroaxonal
damage. Furthermore, the detection ofanti-
GFAP titers in these studies supports the tar-
geting ofthe CNS and astrocytes by heavy
metals (96-98), since astrocytes are exclu-
sively found in the CNS. In this manner,
autoantibodies may provide a means whereby
subcellular targets and the progression of
neuropathy may be documented.
In this context the temporal appearance of
autoantibodies in serum provides information
on the extent oftarget cell involvement and
the progression of insult. For example, it is
likely that anti-NF titers would be the first to
appear with primary neuronal involvement
(e.g., mercury), whereas anti-MBP would
precede all others in the case of primary
demyelination (triethyltin).
Toxic Exposures May
Precipitate Autoimmunity
byAltering Antigen
Immunogenicity
The role of environmental factors in the
production or augmentation ofautoimmune
responses has been suggested for some time.
The interaction ofdrugs or environmental
chemicals, including metals (e.g., gold, mer-
cury, and glomerulonephritis), with endoge-
nous protein constituents may alter their
immunogenicity and result in the induction of
immune responses reflected in the generation
of autoantibodies (108). Having detected
Table 2. Correlation (r) and significance level (p) between autoantibody titers and blood lead in workers occupation-
ally exposed to lead and rats experimentally exposed to lead in the drinking water.
Anti-NF-68 Anti-NF-160 Anti-NF-200 Anti-GFAP Anti-MBP
Human PbB r= 0.5 0.3 0.3 0.1 0.2
(n=50) p= 0.0001 0.002 0.02 NS NS
Rat PbB r= 0.7 0.5 0.7 0.4 0.3
(n=25) p= 0.0001 0.001 0.0001 0.05 0.05
Abbreviations: PbB, blood lead; NS, not statistically significant.
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antibodies to nervous system antigens in
humans and experimental animals, it was
speculated that further alteration of these
antigens may occur with chronic exposures to
neurotoxicants. This may provide a basis for
differential antibody profiles between chemi-
cals. Waterman et al. (123,126) have demon-
strated that in vitro treatment ofthe neural
antigens NFs, MBP, and GFAP with lead,
followed by inoculation of CBA/J mice,
resulted in antibody titers that were signifi-
cantly higher than those produced by the
51~~~A
Figure 5. lgM in splenic supernatant following stimula-
tion of rat (n = 7) splenocytes collected from rats 7 days
after exposure to 450 ppm lead acetate in the drinking
water. Abbreviations: GFAP, glial fibrillary acidic protein;
NF, neurofilaments. Splenocytes were cultured for 72 hr
with lipopolysaccharide in M199 supplemented with 5%
fetal bovine serum. Cell-free supernatants were col-
lected and assayed for autoantibodies to nervous sys-
tem proteins. For further details see Waterman et al.
(126). This verifies the presence of an autoreactive
B-lymphocyte population to nervous system proteins.
Control splenic supernatants did not have detectable
titers uf antibodies to these proteins (see text). Each bar
represents the mean SD.
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Figure 6. Dose-response relationship between clinical
scores and the number of detectable lgG titers against
nervous system proteins in reference, lead-exposed, and
mercury-exposed humans (n = 129). These data indicate
that as more autoantibodies against nervous system
proteins are detected the greater the likelihood of clini-
cal deficits due to greater neurotoxicity, p 0.0001 (see
text). Each bar represents the mean ± SD.
antigens alone. MBP is a negatively charged
18-KD protein with 170 amino acid residues
with no sulfhydryl groups (127). Lead
cations, which are divalent, may bind to two
MBP molecules in a charge neutralization
process (126) to produce a larger, more
immunogenic antigen. In contrast, NFs and
GFAP contain methionine and cysteine
residues with which metals are known to
react (128,129). It is possible that this bind-
ing unmasks new epitopes on the auto-
antigen, rendering it immunogenic or more
immunogenic. This provides evidence that a
known neurotoxic chemical can alter the
immunogenicity ofantigen and enhance the
magnitude ofthe autoimmune response. This
is significant in light ofthe suspected involve-
ment ofheavy metals in autoimmune neuro-
degenerative diseases where environmental
factors may play a role (see "Neurotoxic
Exposures and NeuroimmuneInteractions").
Autoimmune Responses
and the Progression
ofNeurotoxicity
Numerous studies have indicated that
autoantibodies may not simply represent an
epiphenomenon indicative oftissue damage.
Anti-MBP antibodies from MS patients have
been shown to be cytotoxic and are believed
to play a key role in the pathogenesis ofMS
(65,81). Antibodies to dihydropyridine cal-
cium channel (the L channel) from sera of
ALS and Lambert-Eaton syndrome patients
are pathogenic and interfere with nerve con-
duction, synaptogenesis, and neurite growth
(83,84). Furthermore, recent evidence indi-
cates that autoantibodies do not interact with
surface antigens but may penetrate normal
cells, induding neurons, to produce degener-
ation and apoptosis (130-132).
We have shown that the immunoglobulin
fragment from lead-exposed rats attenuates
presynaptic neurotransmission in isolated
neuromuscular preparations (Figure 7) (133).
It did not, however, block muscle responses
postsynaptically, as evidenced by normal
responses toexogenously addedacetylcholine.
Autoantibodies to the presynaptic protein
synaptotagmin were detected in these sera.
Sera ofunexposed rats did not block neuro-
transmission nor did they contain anti-
synaptotagmin antibodies. Synaptotagmin is
a calcium-dependent vesicle protein, a com-
ponent ofthe docking-fusion pore machin-
ery (134,135). Autoantibodies to this
protein or other presynaptic proteins
processed following axonal degeneration in
sera oflead-exposed rats may interfere with
neurotransmitter release. These results are not
surprising with metals. Synapses are a major
site of mercury neurotoxicity (136-138).
Presynaptically, mercury blocks sodium and
calcium channels (139). Lead blocks different
types ofchannels (140,141) and interferes
with calcium regulatory proteins such as pro-
tein kinase C and calmodulin (142,143). In
the course of interactions with these target
proteins and the ensuing neurodegeneration
is an autoimmune response with thepotential
to subsequently target these neuronal mecha-
nisms possible? This would be consistent with
our studies and studies ofsera ofpatients with
Lambert-Eaton syndrome where autoantibod-
ies to synaptotagmin, synaxin, the N, P, and
Q calcium channels have been detected and
shown to interfere with calcium currents and
neurotransmitter release (144-151). In con-
trast, sera from patients with Miller-Fisher
syndrome block neuromuscular transmission
pre- and postsynaptically (152); sera from
ALS patients (153) and diabetic BB/W rats
(154) enhance calcium currents and neuro-
transmitter release.
In contrast to the studies with lead is the
enhancement ofmuscle contractility to elec-
trical stimulation of a nerve-muscle prepara-
tion and to exogenous acetylcholine in the
presence of immunoglobulin from hens
exposed to phenyl saligenin phosphate 21
days earlier (155,156). Sera from these hens
contained antibodies to acetylcholinesterase
(AChE), which wouldexplain these responses
and the inhibition of muscle homogenate
Before After
I 0.5 g Pb 450 ppm serum
Figure 7. Sample trace of an isolated neuromuscular preparation twitch response to electrical stimulation of the
nerve (acetylcholine release) in the absence (before) and presence (after) of a 150-pL lgG fragment isolated from sera
of a rat exposed to 450 ppm lead for 42 days. There was an attenuation of muscle responses in the presence ofthe
immunoglobulin fragment. Sera had detectable titers to nervous system proteins, including synaptotagmin (seetext).
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AChE by the immunoglobulin fragment of
the sera. Pathogenic anti-AChE antibodies
have been reported in several neuropathies
including ALS (157-160). It should be noted
that inhibition ofendothelial AChE by anti-
esterases increases BBB permeability (161).
Sera from these same hens had detectable
autoantibodies to NFs and MBP as early as
seven days following exposure. Titers ofNF
autoantibodies significantly correlated with
clinical deficits. This is consistent with the
axonopathy known to be associated with
some organophosphates.
Immunoglobulins to postsynaptic receptors
have not yet been identified following neuro-
toxic exposures but are likely to play a role in
neuropathy. This is recognized in myasthenia
gravis with autoantibodies to the nicotinic
acetylcholine (ACh) receptor (49), anti-
muscarinic (m)AChR in Chagas disease
(162), and anti-P-adrenoceptors in dilated
cardiomyopathy (163,164).
Another pathogenic role forautoantibodies
is suggested in experiments by Claudio et al.
(165,166). Mice with a duplication of
d-aminolevulinate dehydrogenase (ALAD)
when exposed to lead manifested an increase
in BBB permeability. These animals had sig-
nificant autoantibodies to neural proteins,
particularly GFAP. Immunohistochemistry of
the BBB showed significant presence ofIgG
at the BBB. This was not observed in control
mice or in mice with a single copy of the
ALAD gene. This study suggests that
increased BBB permeability not only exposes
neural epitopes to the immune system, but
that immunoglobulins gain access to the CNS.
The question ofwhether these autoimmune
responses reflect compromised immunoprivi-
lege is partially answered by the detection of
antisperm immunoglobulins in the sera ofthe
same individuals exposed to lead and mercury
(167). The blood-testes barrier is believed to
serve a function similar to that ofthe BBB and
maybeaffectedbymetals.
In addition to the above-described
studies, autoantibodies to nervous system
proteins have been detected in animals
exposed to other inorganic and organic metals
or solvents (168-71) and in humans exposed
to metals orpesticides (172-174).
Conclusions and
Recommendations
The studies discussed in this review illustrate
the utility ofthe immune system's functional
status for developing markers of neurotoxic
effects ofchemicals. They also suggest a role
ofenvironmental chemicals in the develop-
ment of nervous system autoimmune disease
and/or the progression ofneuropathy. In the
case ofthe autoantibody assays, these studies
suggest a promising association between the
appearance of autoantibody titers against
nervous system proteins and exposure to
subclinical levels ofknown neurotoxicants.
Even ifthese humoral responses prove to be
an epiphenomenon, secondary to nervous sys-
tem injury, they would be useful indices of
this injury. Currently, readily accessible and
sensitive markers of neurotoxic insult (i.e.,
prior to overt changes) do not exist. This
would be particularly applicable in efforts to
protect children before severe irreversible
damage occurs. The studies need to be
expanded in terms oftheir validation with
larger populations, delineation ofthe role of
cellular immunity, and the correlation with
neuropathology in experimental studies.
Furthermore, this approach can be expanded
to include other organ systems with charac-
terized organ-specific antigens (e.g., repro-
ductive, cardiovascular, and pulmonary
systems). The use ofthese immunologic indi-
cators to assess organ system integrity follow-
ing chemical exposure provides a relatively
simple, minimally invasive, objective means
of documenting pathogenesis in human
populations and animal studies. The question
ofautoimmune mechanisms as they relate to
neurotoxicity has only begun to be addressed.
Is the immune system a major effector in the
progression ofthe symptoms associated with
chemical-induced neuropathy? This question
has only recently been raised, primarily from
the work presented here. An unequivocal
answer, however, can only be obtained by
mechanistically based research addressing this
question. Initially, studies ofdocumented
neurotoxic agents (e.g., metals, solvents)
should be performed to address the involve-
ment of neuroimmune interactions in the
development ofnervous system disease and to
distinguish between autoimmunity as a phe-
nomenon following degeneration and
autoimmune disease.
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